Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Adam J BroermanInstitute for Protein Design, University of Washington, Seattle, WA, USA. broerman@uw.edu.ORCID 0000-0002-6878-1769
Christoph PollmannDepartment of Biology/Chemistry, Osnabrück University, Osnabrück, Germany.
Yang ZhaoDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-6596-499X
Mauriz A LichtensteinInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID 0000-0002-2124-8262
Mark D JacksonDepartment of Chemistry, University of Washington, Seattle, WA, USA.
Maxx H TessmerDepartment of Chemistry, University of Washington, Seattle, WA, USA.
Won Hee RyuDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, OR, USA.
Masato OgishiDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-2421-7389
Mohamad H AbediInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Danny D SahtoeInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID 0000-0001-9095-0744
Aza AllenInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Alex KangInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID 0000-0001-5487-0499
Joshmyn De La CruzInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Evans BrackenbroughInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Banumathi SankaranMolecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.ORCID 0000-0002-3266-8131
Asim K BeraInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID 0000-0001-9473-2912
Daniel M ZuckermanDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, OR, USA.ORCID 0000-0001-7662-2031
Stefan StollDepartment of Chemistry, University of Washington, Seattle, WA, USA.ORCID 0000-0003-4255-9550
K Christopher GarciaDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-9273-0278
Florian PraetoriusInstitute for Protein Design, University of Washington, Seattle, WA, USA. florian.praetorius@ist.ac.at.ORCID 0000-0002-0806-8101
Jacob PiehlerDepartment of Biology/Chemistry, Osnabrück University, Osnabrück, Germany.ORCID 0000-0002-2143-2270
David BakerInstitute for Protein Design, University of Washington, Seattle, WA, USA. dabaker@uw.edu.ORCID 0000-0001-7896-6217
Funding
X-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Vivian Stojanoff · 2019 to 2026
$38.6M
User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI Nozomi Ando, J Christopher Fromme · 2018 to 2026
$34.2M
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6M
Structure-based engineering of immune cytokine signalingR01AI051321 · NIAID · STANFORD UNIVERSITY · PI Kenan Christopher GARCIA · 2002 to 2026
$5.6M
Structure, function and engineering of immune cytokine receptor signalingR37AI051321 · NIAID · STANFORD UNIVERSITY · PI GARCIA, KENAN CHRISTOPHER · 2013 to 2022
$4.2M
WESTPA: A high-performance framework for simulating at the frontiers of biologyR01GM115805 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LILLIAN T CHONG · 2015 to 2026
$4.0M
De Novo Design of Minibinder Antagonists for COVID-19 and Future PandemicsR01AI160052 · NIAID · UNIVERSITY OF WASHINGTON · PI BAKER, DAVID, FULLER, DEBORAH H. · 2021 to 2025
$3.5M
Equipment Supplement: DEER spectroscopy tools for probing protein conformational dynamicsR35GM151956 · NIGMS · UNIVERSITY OF WASHINGTON · PI Stefan Stoll · 2024 to 2026
$1.4M
High-sensitivity upgrade of DEER/EPR spectrometerS10OD021557 · OD · UNIVERSITY OF WASHINGTON · PI STOLL, STEFAN · 2017 to 2017
$495k
Genetic and immunological dissection of coinhibitory crosstalks between human T cells and cancer cellsK00CA274708 · NCI · STANFORD UNIVERSITY · PI Masato Ogishi · 2024 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Design of facilitated dissociation enables timing of cytokine signalling. · full record | OpenQuestion